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Abstract
Background: Interferon-γ (IFN-γ) is regarded as a potent antitumor agent, but its clinical application is limited by its
short half-life and significant side effects. In this paper, we tried to develop IFN-γ gene therapy by a replication
defective adenovirus encoding the human IFN-γ (Ad-IFNγ), and evaluate the antitumoral effects of Ad-IFNγ on
nasopharyngeal carcinoma (NPC) cell lines in vitro and in xenografts model.
Methods: The mRNA levels of human IFN-γ in Ad-IFNγ-infected NPC cells were detected by reverse
transcription-polymerase chain reaction (RT-PCR), and IFN-γ protein concentrations were measured by
enzyme-linked immunosorbent assay (ELISA) in the culture supernatants of NPC cells and tumor tissues and bloods
of nude mice treated with Ad-IFNγ. The effects of Ad-IFNγ on NPC cell proliferation was determined using MTT
assay, cell cycle distribution was determined by flow cytometry analysis for DNA content, and cells apoptosis were
analyzed by Annexin V-FITC/7-AAD binding assay and hoechst 33342/PI double staining. The anti-tumor effects and
toxicity of Ad-IFNγ were evaluated in BALB/c nude mice carrying NPC xenografts.
Results: The results demonstrated that Ad-IFNγ efficiently expressed human IFN-γ protein in NPC cell lines in vitro
and in vivo. Ad-IFNγ infection resulted in antiproliferative effects on NPC cells by inducing G1 phase arrest and cell
apoptosis. Intratumoral administration of Ad-IFNγ significantly inhibited the growth of CNE-2 and C666-1 cell
xenografts in nude mice, while no significant toxicity was observed.
Conclusions: These findings indicate IFN-γ gene therapy mediated by replication defective adenoviral vector is
likely a promising approach in the treatment of nasopharyngeal carcinoma.
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Background
Nasopharyngeal carcinoma (NPC) is a rare tumor arising
from the epithelium of the nasopharynx. However, it has
a high incidence rate in South China and Southeast Asia
[1]. Radiation therapy is the main strategy for local control
of NPC [2], but the 5-year survival for stage IV NPC is
only 30%. The poor survival is often associated with high
incidences of local, regional and systemic recurrences.
Although concurrent chemoradiotherapy is developed as
a standard treatment approach for advanced NPC,
the outcome isn’t still satisfactory [3]. Therefore, the
development of multidisciplinary therapeutic approaches
is crucial for improvement of survival in NPC patients.
Interferon-γ (IFN-γ), a multifunctional cytokine produced
mainly by T helper cells, cytotoxic T cells and natural
killer cells [4], exerts antiviral, antiproliferative, immuno-
modulatory and antiangiogenesis effects [5]. IFN-γ inhibits
the growth of numerous tumors [6-10] and has been tried
to use in the clinical management of tumors [11-14].
However, the clinical application of recombinant IFN-γ
protein is hampered by its short half-life and significant
side effects. IFN-γ Gene therapy can continuously
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produce and release therapeutic protein in local focus to
overcome the obstacle of recombinant IFN-γ protein
[9,10,15,16].
In this study, we tried to develop IFN-γ gene therapy
by a replication defective adenovirus encoding the human
IFN-γ (Ad-IFNγ) on nasopharyngeal carcinoma (NPC),
our results showed Ad-IFNγ effectively expressed in NPC
cells, significantly inhibited tumor cell proliferation and
induced cell apoptosis in vitro, inhibited the growth of
xenografts in nude mice.
Methods
Materials
Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine
serum, propidium iodide (PI), and TRIzolW reagent were
from Invitrogen (Carlsbad, CA, USA). Reverse Transcription
System and GoTaqW DNA Polymerase were from Promega
(Beijing) Biotech Co., Ltd (Beijing, China). Annexin V-FITC/
7-AAD apoptosis detection kit was from Beckman Coulter,
Inc. (Marseille, France), while Double Stain Apoptosis
Detection Kit (Hoechst 33342/PI) from GenScript USA
Inc. (Piscataway, NJ, USA). Rabbit anti-human Ki-67
polyclonal antibody was from NeoMarkers For Lab Vision
Corporation (Fremont, CA, USA), and Streptavidin-
Horseradish Peroxidase kit from Beijing Zhongshan
Golden Bridge Biotechnology Co. (Beijing, China). In Situ
Cell Death Detection kit was purchased from Roche Ap-
plied Science (Mannheim, Germany). Human interferon-γ
ELISA kit was purchased from Boster (Wuhan, China),
recombinant human interferon-γ (rhIFN-γ) protein was
from Shanghai Clonbiotech. Co., Ltd (Shanghai China). (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) and all other reagents were of molecular biology
grade and obtained from Sigma-Aldrich (Shanghai, China).
Cell lines, recombinant adenoviruses and infection
Human nasopharyngeal carcinoma (NPC) cell lines
CNE-1, CNE-2 and C666-1 were maintained in DMEM
containing 10% fetal bovine serum (FBS) at a humidified
atmosphere with 5% CO2 at 37°C. Replication defective
adenoviruses encoding human interferon-γ (Ad-IFNγ)
and β-galactosidase (Ad-LacZ), kindly provided by
Guangzhou Doublle Bioproducts Co., Ltd., were stored
at -80°C for use.
For adenovirus infection, NPC cells were seeded and
cultured for 24 h, and then removed culture medium,
washed with phosphate buffered saline (PBS) (pH 7.4),
followed by infection with adenovirus in serum-free
DMEM for 3 h. After removal of residual virus by PBS
washing, cells were cultured in normal medium for indi-
cated time before the analyses of IFN-γ expression, cell
proliferation and apoptosis.
Reverse transcription-polymerase chain reaction (PCR)
Cells were harvested and total RNAs were extracted
using TRIzolW reagent according to the manufacture’s
instruction. mRNAs were transcribed into cDNAs and PCR
reactions were carried out using their specific primer pairs:
IFN-γ’s sense, 50- TTCAGCTCTGCATCGTTTTG-30, anti-
sense, 50-TTACTGGGATGCTCTTCGAC-30 (amplicon 473
bp); β-actin’s sense, 50-CGTCTTCCCCTCCATCGTG-30,
antisense, 50- TAGCACAGCCTGGATAGCAAC-30 (ampli-
con 334 bp). Amplification was done with an initial cycle of
95°C for 4 min, followed by 30 cycles of 95°C for 30 s, 55°C
for 50 s, 72°C for 30 s, with a final extension at 72°C for
10 min. PCR products were analyzed by ethidium bromide
staining on 1.5% agarose gels.
Enzyme-linked Immunosorbent Assay (ELISA)
NPC cells were seeded into 6-well plate at a density of
1×105 cells/well for 24 hours and then infected with
adenoviruses as described above. The culture superna-
tants were collected at different time points and IFN-γ
concentration was determined by ELISA according to
the manufacture’s instruction (Boster, Wuhan, China)
(the sensitivity is 15.6 pg/mL).
Cell proliferation analysis
The effect of Ad-IFNγ on NPC cell proliferation was
determined using MTT assay as previously described
[17]. Briefly, cells were seeded in 96-well plates at a
density of 2000 cells/well for 24 hours and then infected
with adenoviruses as described above, followed by incu-
bation for 72 h. Viable cells were stained with MTT for
4 hours and followed by determination of OD570 nm with
a reference wavelength at 630 nm.
Cell cycle distribution and apoptosis analysis
Cell cycle distribution was determined by flow cytometry
analysis for DNA content. Briefly, cells were harvested by
trypsinization and washed by PBS, and followed by fixed in
cold 70% ethanol for 1 hour at 4°C. Cell suspensions were
washed twice in PBS, treated by ribonuclease and followed
by PI staining. And then cells were performed flow cytome-
try analysis for DNA content and cell cycle distribution.
Cells apoptosis were analyzed by Annexin V-FITC/
7-AAD binding assay and hoechst 33342/PI double stain-
ing. Both floating and adherent cells were harvested and
washed by PBS, then followed by staining according to
the manufacture’s instruction. Cells stained with Annexin
V-FITC/7-AAD were analyzed by flow cytometry, while
those stained with hoechst 33342/PI were analyzed by
fluorescence microscopy.
Animal model and experimental design
Female BALB/c nude mice (5-6 weeks old, 18-20 g) were
obtained from Shanghai Slike Experimental Animals Co.
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Ltd. (License No. SCXK(hu)2003-0003), housed and fed
under specific pathogen-free conditions (Certificate No.
26-2004C008) according to protocols approved by the
Sun Yat-sen University Institutional Animal Care and
Use Committee. All of the animal experiments were
performed in accordance with Guidelines for the Welfare
of Animals in Experimental Neoplasia. The pieces (about
1.5 mm in diameter) of CNE-2 or C666-1 tumors, which
were maintained by serial subcutaneous transplantation in
BALB/c nude mice, were subcutaneously transplanted
into the flanks of mice to construct xenograft model.
To test the expression of Ad-IFNγ in vivo, mice were
intratumorally injected with 2×109 pfu in 100 μL of PBS
when CNE-2 xenografts reached an approximate diameter
of 7 mm. Tumor tissues and bloods were collected at dif-
ferent time. IFNγ concentration in the samples was mea-
sured by ELISA.
To assess antitumor effects of Ad-IFNγ in vivo, mice
were randomly assigned into eight groups (7-8 mice per
group) when xenografts reached 4-5 mm diameter. Mice
were treated by weekly intratumoral injection of 100 μL of
PBS, 2×109 pfu (plaque-forming unit) of Ad-LacZ, 2×109
pfu, 1×109 pfu, 5×108 pfu, or 1×108 pfu of Ad-IFNγ (in
100 μL of PBS) per dose respectively; while mice in other
two groups were treated by daily intratumoral injection of
100 μL of normal saline or 1×106 IU/(kg body weight) of
rhIFN-γ protein per dose respectively. The treatment was
performed for three consecutive weeks, every injection was
distributed equally into each half (8-12 mm of diameter) or
quadrants (>12 mm of diameter) of tumors. Body weight
and tumor size were measured every 4-5 days, and tumor
xenografts were weighed at the end point of experiments.
Histological analysis
Tumor tissue was fixed in buffered formalin and embedded
in paraffin. Sections (5 μM thick) were mounted on Poly-L-
Lysine treated slides, standard H&E staining was utilized
for histopathological assay. Human Ki67 immunohisto-
chemistry was performed for cell proliferation assay, while
TUNEL labeling was done using a fluorescent in situ cell
death detection kit for apoptosis analysis in tumor tissues.
Statistical analysis
All experiments were repeated at least three times. The
data were analyzed with One-way ANOVA or t test by
using SPSS 10.0 for Windows software (SSPS Inc., Chicago,
IL, USA). P < 0.05 was considered statistically significant.
Results
Ad-IFNγ efficiently expressed hIFNγ in NPC cells
To evaluate the capability of Ad-IFNγ expressed transgenic
product in nasopharyngeal carcinoma (NPC) cells, we
firstly investigated IFNγ mRNA levels in CNE-2 cells after
Ad-IFNγ infection at different multiplicities of infection
(MOIs) at different time. The results showed that Ad-IFNγ
efficiently transcribed human IFNγ gene in CNE-2 cells at
a dose-dependent manner (Figure 1A), hIFNγ mRNA was
detected as early as 8 hours after Ad-IFNγ infection, the
levels reached the top at 48 hours after infection, and then
gradually decreased, while No IFNγ mRNA was detected
in Ad-LacZ-infected cells (Figure 1B).
We investigated IFNγ expression at protein levels in
CNE-1, CNE-2 or C666-1 infected by Ad-IFNγ, and
found that IFNγ protein concentration in the superna-
tants of NPC cells continuously increased within
72 hours post-infection (Figure 1C). The differences
from IFNγ mRNA which peaked at 48 hours may be due
to the instability of the mRNA. No IFNγ proteins were
found in the supernatants of Ad-LacZ-infected NPC
cells (data not shown).
Ad-IFNγ inhibited the proliferation of NPC cells in vitro
We evaluated the effects of Ad-IFNγ on the proliferation of
nasopharyngeal carcinoma (NPC) cells by MTT assay after
72 h after Ad-IFNγ infection. The anti-proliferative effects
of Ad-IFNγ on NPC cells were shown in Figure 2A. Ad-
IFNγ inhibited the proliferation of CNE-1, CNE-2 and
C666-1 NPC cell lines from 1 to 100 MOIs at a dose-
dependent manner. No significant inhibition was observed
on NPC cells after infection with 50 MOIs of Ad-LacZ.
To explore the mechanism involved in proliferation
inhibition of Ad-IFNγ on NPC cells, the cell cycle
profiles were analyzed by flow cytometry for DNA
contents on NPC cells after infection with 100 MOIs of
adenoviruses for 72 h. The results showed a significantly
higher percentage at the G1 phase in the cells infected
with Ad-IFNγ than those in Ad-LacZ infected cells
(CNE-2: 70.8% ± 6.3% vs 56.1% ± 5.9%, p<0.05; C666-1:
75.8% ± 6.9% vs 62.0% ± 4.8%, p<0.05) (Figure 2B).
These indicated that Ad-IFNγ possesses an effect of G1
phase arrest on NPC cells.
Ad-IFNγ induced the apoptosis of NPC cells in vitro
To examine the fate of Ad-IFNγ-infected NPC cell lines,
an Annexin V/7-AAD binding assay and Hoechst
33342/PI double staining were performed after treat-
ment with 100 MOIs of adenoviruses for 72 h. The
results showed that there was an increased fraction of
Annexin V+/7-AAD− (early apoptosis) and Annexin V+/7-
AAD+ (late apoptosis) in Ad-IFNγ-infected NPC cells
than those of Ad-LacZ-infected cells (CNE-2, 21.2% vs
5.3%, p<0.01; C666-1, 16.3% vs 6.4%, p<0.01) (Figure 3A).
In Hoechst 33342/PI double staining assay, there were
higher percentages of bright blue cells (apoptosis) in NPC
cells infected with Ad-IFNγ than those with Ad-LacZ
(CNE-2, 25.2% vs 4.8%, p<0.01; C666-1, 19.5% vs 3.0%,
p<0.01) (Figure 3B). These data suggested that Ad-IFNγ
induced the apoptosis in NPC cells.
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Ad-IFNγ efficiently expressed human IFNγ in NPC
xenografts in nude mice
To evaluate the dynamic expression of AdIFNγ in vivo,
we measured the levels of hIFNγ in tumor and blood
samples collected from nude mice carrying CNE-2 NPC
xenografts on days 1, 3, 5 and 7 after intratumoral injection
with Ad-IFNγ. The results showed that Ad-IFNγ efficiently
expressed hIFNγ in NPC xenografts, the concentration of
hIFNγ in tumor tissue was (136.5±25.5) pg/(mg tissue) at
24 hours post-injection of AdIFNγ, reached the peak of
(265.8±26.2) pg/(mg tissue) at 72 hours, and then
decreased gradually to (61.1±8.3) pg/(mg tissue) at day 7
(Figure 4A). hIFNγ were also detected in blood. As same
as in tumor tissue, the concentration of hIFNγ reached the
peak of (64.9±15.9) pg/mL after 3 days post-injection, and
then decreased gradually to (18.9±7.3) pg/mL at day 7.
Ad-IFNγ inhibited the growth of human NPC xenografts
Administration of Ad-IFNγ resulted in significant
growth suppression of NPC xenografts compared to the
control groups. As shown in Figure 5A and 5B, tumor
growth in the Ad-IFNγ-treated groups was significantly
slower than that in Ad-LacZ (vector control) group or
PBS (medium control) group. The inhibition effects
showed a clear dose-dependent manner. At the end of
experiment, the tumor weights in Ad-IFNγ groups were
significantly lighter than those in Ad-LacZ or PBS group
(Figure 5C and 5D), 1×108, 5×108, 1×109 and 2×109 pfu/
dose of Ad-IFNγ treatment respectively produced 24.1%,
43.2%, 64.8%, and 73.5% of growth inhibition for CNE-2
xenografts (Figure 5C), 42.6%, 54.3%, 71.3% and 81.7%
of growth inhibition for C666-1 xenografts (Figure 5D).
However, 2×109 pfu/dose of Ad-LacZ barely inhibited
tumor growth. The efficacy of daily intratumoral injection
of 1×106 IU/(kg body weight)/day of rhIFNγ was likely
similar with that of the administration of 5×108 pfu/dose/
week of Ad-IFNγ. There were no significant differences
on body weights between Ad-IFNγ-treated and Ad-LacZ
or PBS-treated mice (P>0.05, data not shown), which
indicated low general toxicity on Ad-IFNγ treatment.
Representative tumors harvested from each group
were processed for histological analyses. Pathologic ana-
lysis (via H&E staining) found that there were large areas
of necrosis in the tumor tissue treated with Ad-IFNγ,
while few necrotic areas were observed in the Ad-LacZ-
treated and PBS-treated tumors (data not shown). Cell
proliferation was estimated by the immunohistochemical
assessment of the nuclear antigen Ki-67. The results
showed that Ki-67 was significantly lower in tumor
tissue treated with Ad-IFNγ than those in Ad-LacZ
group and PBS group. For apoptosis analysis, TUNEL
positive ratios were significantly higher in Ad-IFNγ
groups than those in Ad-LacZ group and PBS group.
The representative pictures for Ki-67 and TUNEL staining
in PBS group, Ad-LacZ group, and 1×109 pfu Ad-IFNγ
group were shown in Figure 6.
Figure 1 Ad-IFNγ effectively expressed human IFN-γ in NPC cells. (A) Dose-dependent IFN-γ expression at mRNA level. After CNE-2 cells
were infected with Ad-IFNγ at different multiplicities of infection (MOIs) (20 MOIs of Ad-LacZ as negative control) for 24 hours, human IFNγ mRNA
levels were detected by RT-PCR in CNE-2 cells (IFNγ 473 bp; human β-actin as internal control, 334 bp). (B) Time course of IFN-γ expression at
mRNA level. IFNγ mRNA levels were detected by RT-PCR in CNE-2 cells infected with 50 MOIs of Ad-IFNγ for 8, 24, 48 or 72 hours, CNE-2 cells
infected with 50 MOIs of Ad-LacZ for 48 hours were used as negative control. (C) IFN-γ expression at protein levels in NPC cells. CNE-1 (left),
CNE-2 (middle) or C666-1 (right) cells were infected with Ad-IFNγ at indicated MOIs, the culture supernatants were then sampled at different time
points, and IFN-γ concentrations in the supernatants were detected by ELISA (Boster, Wuhan, China). IFN-γ expression efficiency was displayed as
ng/106 cells.
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Discussion
Interferon-γ (IFN-γ), as a multifunctional cytokine,
exerts diverse biological functions related to host defense
and immune regulation, such as inflammation, innate
and acquired immunity, cell cycle and apoptosis [5].
IFN-γ plays a critical role in promoting protective host
responses to tumors, which proposed mechanisms
include, (a) anti-proliferative and pro-apoptotic actions,
(b) anti-angiogenesis in tumors, and (c) promoting both
the innate and adoptive immune responses against
tumors [20,21].
Although IFN-γ has been investigated as a potential
therapeutics for various types of tumors [6-13], the
attempts to improve antitumor efficacy by increasing the
dose or by repetitive continuous administration resulted
in higher toxicity and low efficacy [22]. Considerable
experimental data from our group and other investigators
demonstrated that intratumoral IFN-γ gene transfer to
achieve long-term, continuous locoregional exposure of
IFN-γ is likely an appropriate approach for improving
efficacy and reducing toxicity of IFN-γ [9,10,15,16,23,24].
In this study, we reported that adenovirus-mediated IFN-γ
gene transfer (Ad-IFNγ) inhibited tumor growth of human
nasopharyngeal carcinoma (NPC) cells (Figure 2 and
Figure 5). Here the anti-NPC activity of IFN-γ included
not only direct anti-proliferative and pro-apoptotic actions,
also indirect mechanisms, such as immunomodulation and
antiangiogenesis.
Ad-IFNγ efficiently expressed human IFN-γ in naso-
pharyngeal carcinoma cells in vitro and in vivo (Figure 1
and Figure 3), and exhibited strong antiproliferative
effects (Figure 2A and Figure 6). According to previous
reports, the antiproliferative mechanisms of IFN-γ seem
to be cell type specific [9,25-29], either induction of cell
Figure 2 Ad-IFNγ inhibited the proliferation of NPC cells by inducing G1 phase arrest in vitro. (A) Cell viability assay. CNE-2 or C666-1 cells
were infected with Ad-IFNγ at different MOIs for 72 h, followed by MTT assay for cell viability. (B) Cell cycle distribution. CNE-2 or C666-1 cells
were infected with Ad-IFNγ at 50 MOIs for 48 h, followed by flow cytometry analysis for DNA content and cell cycle distribution as described in
“Materials and methods”. * p < 0.05, ** p < 0.01 while compared with corresponding cells infected with Ad-LacZ, N=3.
Liu et al. Journal of Translational Medicine 2012, 10:256 Page 5 of 9
http://www.translational-medicine.com/content/10/1/256
cycle arrest or apoptosis. Here we found that both
G1 phase arrest and apoptosis contributed to Ad-
IFNγ-mediated growth suppression in NPC cell lines
(Figure 2B, Figure 3 and Figure 6), consistent with the
report that the antiproliferative effects of minicircle-
IFNγ on NPC cell lines could be attributed to G1 arrest
and apoptosis [9]. The JAK/STAT pathway may be
responsible for most biological effects mediated by IFN-γ
[20,30], which regulates different cell cycle-associated
proteins that control the G1-S checkpoint [25], or in-
duce cell apoptosis through up-regulating the expres-
sion of various apoptosis-related proteins in different
cell types [31-33].
Although antiproliferation and apoptosis induction were
main effects of Ad-IFNγ-mediated anti-NPC in this study,
antiangiogenesis may contribute also to growth inhibition
of NPC xenografts in nude mice. Because the microvessel
densities (MVDs) were found to be decreased in the xeno-
grafts treated with Ad-IFNγ compared with those treated
with Ad-LacZ or PBS in our study (data not shown).
Previous studies reveal that IP-10, an inhibitor of angio-
genesis, could be induced by IFN-γ in endothelial cells
and exert potent antiangiogenesis activity by inhibiting
endothelial cell differentiation, motility and tube forma-
tion [34,35]. However, due to highly species specificity,
human unlikely exerts direct effects on murine vascular
Figure 3 Ad-IFNγ induced apoptosis in NPC cells. Both floating and adherent NPC cells were harvested after infection with 50 MOI of Ad-IFNγ
or Ad-LacZ for 72 hr, washed with ice-cold PBS and followed by apoptosis analysis. (A) Annexin V-FITC/7-AAD binding assay by flow cytometry.
5×105 of collected cells were incubated in the dark for 15 minutes with 100 μL of 1×Binding Buffer containing 10 μL of Annexin V-FITC and
20 μL of 7-ADD Viability Dye (Beckman-Coulter, Inc. Marseille, France) on ice. Samples were diluted with 400 μL of 1×Binding Buffer and
immediately analyzed by a Coulter Epics Altra flow cytometer (Beckman-Coulter). Left, Diagrams in a representative experiment. Annexin V+/7-
AAD− indicates early apoptotic cells, and Annexin V+/7-AAD+ indicates late apoptotic cells. Right, Statistical analysis of Annexin V-positive cells
(apoptotic cells) generated from three independent experiments. (B) Hoechst 33342/PI double staining. Collected cells were adjusted to the
density of 1×106 cells/mL in PBS with 1% FBS and stained with 5 μM of Hoechst 33342 at 37°C for 10 min. And then cells were stained with
1 μM of PI for 10 min at room temperature after washing with PBS to remove Hoechst dye. The stained cells were mounted onto a polylysine-
coated slide and examined under a fluorescent microscope. A total of 300~400 nuclei from 5~8 randomly chosen fields were examined. High
blue fluorescent indicates apoptotic cells (bright blue arrow), low blue indicates live cells (azury arrow), while red represents dead cells (pink
arrow). Apoptosis was expressed as a percentage of the total number of nuclei examined. Left, Representative pictures from one experiment.
Right, Statistical analysis of apoptotic cells from three independent experiments. ** p<0.01, compared with Ad-LacZ-treated cells.
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system, but likely acts on tumor cells to indirectly regulate
angiogenesis. It was reported that IFN-γ acted as antian-
giogenic cytokine by inhibiting the expression of angio-
genic factors, such as VEGF or perlecan, in renal cell
carcinoma [36], stromal fibroblasts [37], human cornea
[38], and WiDr/HT29 colon carcinoma cells[39], or by in-
ducing the expression of anti-angiogenic factor monokine
induced by interferon-gamma (MIG, or CXCL9) in non-
small cell lung carcinom [40]. Here we would like to make
a hypothesis that IFN-γ may exert antiangiogenic effect in
nude mice carrying NPC xenografts by regulating the
expression of some angiogenic or antiangiogenic factors in
NPC cells. This hypothesis, of course, needs to be tested
and verified.
Human and murine IFN-γ display low level of sequence
homology (only 40%) at protein level, which explains why
the human and murine proteins display a strict species
specificity in their ability to bind to and activate human
and murine cells [41]. So human IFN-γ has less activity in
the nude mouse host, though nude mice display potent
macrophage and NK cell activity [42-44] and remain some
basal T-cell function [45]. Direct immunomodulation on
mouse immune system by human IFN-γ unlikely contri-
butes to its antitumor effects. However, we cannot exclude
Figure 4 Ad-IFNγ effectively expressed human IFN-γ in NPC xenografts in nude mice. Mice were intratumorally injected with 2×109 pfu of
Ad-IFNγ, and then collected tumor tissues (A) and bloods (B) 1 day, 3, 5 and 7 days after Ad-IFNγ injection (mice before injection marked “day 0”
as negative control, 3-4 mice per time point). Tumor tissues were made into homogenates in cold PBS, and then human IFNγ concentrations in
the tissue homogenates and blood plasmas were measured by using human interferon-γ ELISA kit (Boster, Wuhan, China).
Figure 5 Ad-IFNγ inhibited the growth of human NPC xenografts. When CNE-2 or C666-1 xenografts reached 4-5 mm diameter, mice were
randomly assigned (7~8 mice per group) and treated by weekly intratumoral injection of 100 μL of PBS, Ad-LacZ or Ad-IFNγ (in 100 μL of PBS) or
by daily intratumoral injection of 100 μL of normal saline (NS) or rhIFN-γ protein (in 100 μL of NS), respectively. (A, B) Tumor growth curves.
Tumor size was measured every 4 days for CNE-2 xenografts (A) or 5 days for C666-1 (B), and the volume (V) was calculated according to the
following formula: V = 0.52 × length × width2 [18,19]. (C, D) Tumor weights. After 3 weeks of treatment, mice with CNE-2 (C) or C666-1 (D)
xenografts were sacrificed and tumor tissues were resected followed by weighing. (* p < 0.05, ** p < 0.01 compared with corresponding media).
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the possibility that other indirect effects are involved in
Ad-IFNγ-mediated antitumor immune response. Firstly,
human IFN-γ could modify the expression of MHC and
costimulatory molecules or cytokines, chemokines on
human NPC cells [21,46], which may activate the residual
immune system of nude mice. Secondly, adenoviral vector
and heterogenous IFN-γ expression likely induce a nonspe-
cific immune response directed by NK and/or microphage
cells in nude mice [47].
Taken together, Ad-IFNγ displayed efficient anti-NPC
activities by inhibiting tumor cell proliferation and
induced cell apoptosis in this study. Additional indirect
effects on antiangiogenesis and immunomodulatory may
also be involved in this antitumor activity. So IFN-γ gene
therapy by a replication defective adenovirus encoding
the human IFN-γ (Ad-IFNγ) is likely a potential novel
therapeutics on comprehensive therapy of nasopharyngeal
carcinoma.
Nevertheless, recent reports have shown that the
immune response activated by IFN-γ plays a dual role in
cancer: It can not only suppress tumor growth by
destroying cancer cells or inhibiting their outgrowth but
also promote tumor progression either by selecting for
tumor cells that are more fit to survive in an immuno-
competent host or by establishing conditions within the
tumor microenvironment that facilitate tumor out-
growth [48]. IFN-γ treatment is a double-edged sword
whose anti- and protumorigenic activities are dependent
on the cellular, microenvironmental, and/or molecular
context [30]. Thereby, more investigations should be
carried out to clarify the influences of cellular, microen-
vironmental, immunological and molecular events on
the anti-NPC effects of Ad-IFNγ before its clinical
application.
Conclusions
The results of the present study indicate that Ad-IFNγ
likely performs potent anti-nasopharyngeal carcinoma
effects by inhibiting cell proliferation, inducing G1 phase
arrest and cell apoptosis. These findings have implications
for the use of IFN-γ gene therapy mediated by replication
defective adenoviral vector as a promising approach in the
treatment of nasopharyngeal carcinoma.
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Figure 6 Histological analysis in C666-1 xenografts. C666-1
xenografts were resected at the end point of experiments, fixed and
embedded in paraffin. Sections (5 μM thick) were mounted on Poly-
L-Lysine treated slides. Upper, Ki67 expression assay. Sections were
microwaved for 10 min for “antigen retrieval” and incubated with
Ki67 antibody (1:200), followed by visualization with DAB using a
Streptavidin-Horseradish Peroxidase kit. Lower, TUNEL labeling for
apoptosis analysis. TUNEL labeling was performed with a fluorescent
in situ cell death detection kit, according to the manufacturer’s
instruction (Roche Applied Science, Germany).
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